| Founded | 2010, Qingdao, China |
|---|---|
| Global Reach | 100+ countries |
| Certifications | GMP, FDA VMF, CEP, ISO |
| Core Products | UDCA, veterinary APIs, antibiotics, nutrition ingredients |
| Middle East-Specific | Halal certification, SFDA/GCC compliance |
The GCC pharmaceutical market was valued at USD 23.7 billion in 2024 and is projected to reach USD 48.98 billion by 2033, growing at a CAGR of 7.6%. Saudi Arabia alone commands approximately 46.5% of the regional market. This growth is driven by Saudi Vision 2030's pharmaceutical localization targets, the UAE's emergence as a life sciences hub, and rising healthcare expenditure across all six GCC states. As of 2024, Saudi Arabia had 56 licensed pharmaceutical factories with total investments exceeding SR 7 billion (USD 1.86 billion), up from just a handful a decade ago.
KingWish has been a trusted API supplier to Middle Eastern pharmaceutical manufacturers for over a decade. We understand the specific requirements of the Gulf market: SFDA and GCC drug registration documentation, halal compliance where applicable, logistics routing through Jebel Ali as the regional distribution hub, and the quality expectations of manufacturers serving government tender markets. Unlike suppliers new to the region, we have supported GCC product registrations and understand the authentication requirements for GMP certificates, CPPs, and other regulatory documents that Gulf authorities require.
Saudi Arabia currently imports more than 70% of its pharmaceutical needs, creating a substantial opportunity for qualified API suppliers as the Kingdom pursues its target of 40% domestic production under Vision 2030. The UAE's pharmaceutical sector, anchored by Dubai Science Park and Abu Dhabi's growing biomanufacturing capacity (including the region's first GMP biopharma facility through Mubadala's partnership with National Resilience), represents another growth vector. KingWish is positioned to serve both established and emerging GCC pharmaceutical manufacturers with consistent quality, competitive lead times, and full regulatory support.
GCC pharmaceutical manufacturers cover a broad therapeutic range including hepatology, anti-infectives, metabolic disease, and veterinary medicine. KingWish's portfolio is aligned with the region's highest-demand categories.
UDCA for hepatobiliary formulations treating PBC and gallstone dissolution. With rising liver disease prevalence in the GCC (linked to high rates of metabolic syndrome and NAFLD), UDCA demand is growing across the region. KingWish is China's largest UDCA supplier with CEP certification.
Spectinomycin HCl, amoxicillin trihydrate, tilmicosin phosphate, and gentamycin sulphate. The GCC's growing poultry and livestock sectors — particularly in Saudi Arabia, where the government targets self-sufficiency in poultry production — drive consistent demand for veterinary APIs.
Amoxicillin trihydrate, ampicillin trihydrate, azithromycin dihydrate, amikacin sulphate, and ceftiofur HCl. GCC countries maintain high per-capita antibiotic consumption, and local manufacturing is a priority under national pharmaceutical security strategies.
Amino acids, vitamins, and mineral premixes for the GCC's expanding nutraceutical and animal feed sectors. The region's food supplement market is growing at over 8% annually, supported by health-conscious consumer trends and government wellness initiatives.
Market context: The GCC's pharmaceutical import dependency creates significant opportunities for qualified API suppliers. Saudi Vision 2030's Health Sector Transformation Program aims to increase the healthcare sector's GDP contribution from SAR 199 billion to SAR 318 billion by 2030. The SFDA has streamlined drug registration processes and introduced local-content pricing incentives. Strategic partnerships — such as Sanofi's vaccine localization deal with Arabio and Lifera covering seven vaccines — signal the region's commitment to building a self-sufficient pharmaceutical manufacturing base.
Drug registration in GCC markets requires documentation packages that differ from Western regulatory systems. KingWish has extensive experience supporting product registrations with Gulf regulatory authorities.
We prepare SFDA-specific documentation packages including the Certificate of Pharmaceutical Product (CPP) from China's NMPA, GMP certificate with CCPIT authentication, and comprehensive Drug Master File. Our regulatory team is familiar with SFDA's e-submission portal and document attestation requirements.
For products registered through the GCC Central Committee for Drug Registration, we provide documentation aligned with the unified Gulf registration requirements, including stability data per GCC climate zone (Zone IVa — hot/humid conditions) per ICH Q1 guidelines.
We provide halal certification for applicable products and declarations of synthetic origin for chemically synthesized APIs. Our quality team works with recognized halal certification bodies. For fermentation-derived products, we arrange accredited halal certification.
KingWish holds active CEP certifications recognized by Gulf regulatory authorities. For APIs covered by a CEP, the registration process is streamlined. We provide ICH Q7 GMP certificates, site master files, and quality agreements tailored to GCC requirements.
Payment terms: T/T (wire transfer) or irrevocable Letter of Credit through GCC banks. Minimum order quantities vary by product. Sample quantities available for initial evaluation. For GCC buyers, we ensure all commercial documentation is attested as required by destination country regulations.